JP5583575B2 - 感染症と関連炎症過程の治療のためのタンパク質生成物 - Google Patents

感染症と関連炎症過程の治療のためのタンパク質生成物 Download PDF

Info

Publication number
JP5583575B2
JP5583575B2 JP2010500302A JP2010500302A JP5583575B2 JP 5583575 B2 JP5583575 B2 JP 5583575B2 JP 2010500302 A JP2010500302 A JP 2010500302A JP 2010500302 A JP2010500302 A JP 2010500302A JP 5583575 B2 JP5583575 B2 JP 5583575B2
Authority
JP
Japan
Prior art keywords
lps
rscd6
protein
binding
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010500302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522728A (ja
JP2010522728A5 (https=
Inventor
フォルネス， マリア ロサ サリアス
ソト， フランシスコ ロサノ
Original Assignee
ユニベルシダード デ バルセロナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシダード デ バルセロナ filed Critical ユニベルシダード デ バルセロナ
Publication of JP2010522728A publication Critical patent/JP2010522728A/ja
Publication of JP2010522728A5 publication Critical patent/JP2010522728A5/ja
Application granted granted Critical
Publication of JP5583575B2 publication Critical patent/JP5583575B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010500302A 2007-03-28 2008-03-27 感染症と関連炎症過程の治療のためのタンパク質生成物 Expired - Fee Related JP5583575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200700893 2007-03-28
ES200700893 2007-03-28
PCT/ES2008/000177 WO2008119851A1 (es) 2007-03-28 2008-03-27 Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Publications (3)

Publication Number Publication Date
JP2010522728A JP2010522728A (ja) 2010-07-08
JP2010522728A5 JP2010522728A5 (https=) 2011-05-06
JP5583575B2 true JP5583575B2 (ja) 2014-09-03

Family

ID=39807834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500302A Expired - Fee Related JP5583575B2 (ja) 2007-03-28 2008-03-27 感染症と関連炎症過程の治療のためのタンパク質生成物

Country Status (6)

Country Link
US (1) US8691752B2 (https=)
EP (1) EP2143436B1 (https=)
JP (1) JP5583575B2 (https=)
CA (1) CA2681828A1 (https=)
ES (1) ES2550389T3 (https=)
WO (1) WO2008119851A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119851A1 (es) * 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
JP2014516046A (ja) * 2011-05-26 2014-07-07 フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質ｃｄ５又はｃｄ６
JP2019535834A (ja) 2016-11-18 2019-12-12 ユニベルシタ デ バルセロナ 感染症及び関連炎症プロセスの処置のためのｃｄ６及びイミペネムの併用療法
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315999B1 (en) * 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
WO1993019772A1 (en) 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2175247A1 (en) 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
CA2268085A1 (en) * 1996-10-22 1998-04-30 Go Wakabayashi Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6172220B1 (en) * 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
US20030114377A1 (en) * 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
EP1278749B1 (en) * 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
US6729735B2 (en) 2001-06-28 2004-05-04 Plx, Inc. Lateral transfer retroreflector assembly and method of assembling the same
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2008119851A1 (es) * 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
ES2336752B1 (es) * 2008-06-20 2011-05-11 Hospital Clinic I Provincial De Barcelona Composiciones farmaceuticas de cd5.

Also Published As

Publication number Publication date
JP2010522728A (ja) 2010-07-08
US20100105622A1 (en) 2010-04-29
ES2550389T3 (es) 2015-11-06
CA2681828A1 (en) 2008-10-09
EP2143436A1 (en) 2010-01-13
US8691752B2 (en) 2014-04-08
WO2008119851A1 (es) 2008-10-09
EP2143436A4 (en) 2013-11-20
EP2143436B1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
US6562784B1 (en) Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
Schleicher et al. Platelets induce apoptosis via membrane-bound FasL
US9649357B2 (en) Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
US20190010193A1 (en) Derivative Peptide Compounds and Methods of Use
KR20180094913A (ko) 보체 활성의 조절인자
CN102413836A (zh) 与补体系统活性过高有关的疾病的治疗
JP2022547050A (ja) 治療用融合タンパク質
JP2018524402A (ja) 合成ペプチド化合物及び使用方法
JP5583575B2 (ja) 感染症と関連炎症過程の治療のためのタンパク質生成物
Bierschenk et al. C4b-binding protein inhibits particulate-and crystalline-induced NLRP3 inflammasome activation
US20140249087A1 (en) Use of hemopexin to sequester hemoglobin
US10975131B2 (en) Factor H-Fc immunotheraphy
JP2020524144A (ja) 微生物性炎症を処置するための方法および組成物
US12297235B2 (en) Synthetic peptide compounds and methods of use
JP6288815B2 (ja) 肺炎等を治療するための医薬組成物
US11324804B2 (en) Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
KR20110124060A (ko) Ｗｔａ를 유효성분으로 함유하는 백신 조성물
WO2016056665A1 (ja) 白血球の細胞外トラップ形成の阻害剤
JP7358695B2 (ja) 血栓性微小血管症治療における使用のためのクラスタリン
JP2005523879A (ja) Ｓｉｒｓ／ｓｅｐｓｉｓを治療及び予防するための組成物及び方法
Nusbaum et al. Workshop 1: Phagocyte biology: from gene to function
Myhre GRAM-POSITIVE ENDOTOXEMIA AND MODULATION OF THE INNATE IMMUNE RESPONSE
De Novo Acute Kidney Injury et al. TH-FC001
WO2011038537A1 (zh) 败血症以及败血症休克的预测、预防和治疗方法及试剂盒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140716

R150 Certificate of patent or registration of utility model

Ref document number: 5583575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees